君实生物肾癌免疫疗法获批上市标志着国内创新药物新突破

和讯网04-08

快讯正文君实生物肾细胞癌免疫疗法获批上市投资者关注的热点栏目显示，君实生物近日发布公告。公司已收到国家药品监督管理局颁发的《药品注册证书》。该证书标志着特瑞普利单抗与阿昔替尼联合疗法，用于治疗中高危不可切除或转移性肾细胞癌患者。这成为国内首个获得批准的肾癌免疫疗法。二级市场投资者对此类重要信息增量内容需保持敏锐。此次获批的疗法，将为肾细胞癌患者提供新的治疗选择。和讯自选股写手风险提示：以上内容仅...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2425606664?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-08 08:28","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2425606664","market":"hk","top_or_hot":-1,"title":"君实生物肾癌免疫疗法获批上市 标志着国内创新药物新突破","media":"和讯网","content":"<div>\n<p>快讯正文君实生物肾细胞癌免疫疗法获批上市投资者关注的热点栏目显示，君实生物近日发布公告。公司已收到国家药品监督管理局颁发的《药品注册证书》。该证书标志着特瑞普利单抗与阿昔替尼联合疗法，用于治疗中高危不可切除或转移性肾细胞癌患者。这成为国内首个获得批准的肾癌免疫疗法。二级市场投资者对此类重要信息增量内容需保持敏锐。此次获批的疗法，将为肾细胞癌患者提供新的治疗选择。和讯自选股写手风险提示：以上内容仅...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404080914548afc757c&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>君实生物肾癌免疫疗法获批上市 标志着国内创新药物新突破</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n君实生物肾癌免疫疗法获批上市 标志着国内创新药物新突破\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-08 08:28 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404080914548afc757c&s=b><strong>和讯网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>快讯正文君实生物肾细胞癌免疫疗法获批上市投资者关注的热点栏目显示，君实生物近日发布公告。公司已收到国家药品监督管理局颁发的《药品注册证书》。该证书标志着特瑞普利单抗与阿昔替尼联合疗法，用于治疗中高危不可切除或转移性肾细胞癌患者。这成为国内首个获得批准的肾癌免疫疗法。二级市场投资者对此类重要信息增量内容需保持敏锐。此次获批的疗法，将为肾细胞癌患者提供新的治疗选择。和讯自选股写手风险提示：以上内容仅...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404080914548afc757c&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404080914548afc757c&s=b","article_id":"2425606664","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404080914548afc757c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2425606664","pubTimestamp":1712536110,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"快讯正文君实生物肾细胞癌免疫疗法获批上市投资者关注的热点栏目显示，君实生物近日发布公告。公司已收到国家药品监督管理局颁发的《药品注册证书》。该证书标志着特瑞普利单抗与阿昔替尼联合疗法，用于治疗中高危不可切除或转移性肾细胞癌患者。这成为国内首个获得批准的肾癌免疫疗法。此次获批的疗法，将为肾细胞癌患者提供新的治疗选择。和讯竭力但不能证实上述内容的真实性、准确性和原创性，对此和讯不做任何保证和承诺。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688180":"君实生物","BK1583":"高瓴概念","BK1515":"抗疫概念","BK1161":"生物科技","06978":"永泰生物-B","BK1574":"生物医药B类股","01877":"君实生物"},"translate_title":"The approval of Junshi biological renal cell carcinoma immunotherapy marks a new breakthrough in innovative drugs in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688180":0.9,"01877":1,"06978":1},"content_text":"快讯正文君实生物肾细胞癌免疫疗法获批上市投资者关注的热点栏目显示，君实生物近日发布公告。公司已收到国家药品监督管理局颁发的《药品注册证书》。该证书标志着特瑞普利单抗与阿昔替尼联合疗法，用于治疗中高危不可切除或转移性肾细胞癌患者。这成为国内首个获得批准的肾癌免疫疗法。二级市场投资者对此类重要信息增量内容需保持敏锐。此次获批的疗法，将为肾细胞癌患者提供新的治疗选择。和讯自选股写手风险提示：以上内容仅作为作者或者嘉宾的观点，不代表和讯的任何立场，不构成与和讯相关的任何投资建议。在作出任何投资决定前，投资者应根据自身情况考虑投资产品相关的风险因素，并于需要时咨询专业投资顾问意见。和讯竭力但不能证实上述内容的真实性、准确性和原创性，对此和讯不做任何保证和承诺。下载和讯APP查看快讯，体验更佳>>","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2425606664"}

君实生物肾癌免疫疗法获批上市 标志着国内创新药物新突破

精彩评论

君实生物肾癌免疫疗法获批上市标志着国内创新药物新突破